|
Depressive Symptoms
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The 7-item Generalized Anxiety Disorder Scale (GAD-7) and the 9-item Patient Health Questionnaire (PHQ-9) were used to assess the anxiety and depressive symptoms of the mothers of the autistic children.
|
31393408 |
2019 |
|
Depressive Symptoms
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
There was no correlation between severity of depressive symptoms (as assessed by GDS-30 and BDI) with anxiety and depressive symptoms except for significant correlation between BDI total score and GAD-7 total score (Pearson correlation coefficient-0.319;p = 0.003).Factor analysis of GDS-30 yielded a five factor solution and when the items of other 3 scales were added, the number of factors/symptoms clusters increased to 7.
|
30054249 |
2019 |
|
Depressive Symptoms
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The GAD-7 Scale was used to assess the anxiety level, and PHQ-2 was used to assess the depressive symptoms.
|
31532238 |
2019 |
|
Depressive Symptoms
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Hearing performance was assessed with Freiburg monosyllabic test and Oldenburg inventory (OI); the health-related quality of life was measured with Nijmegen Cochlear Implantation Questionnaire (NCIQ); depressive symptoms with General Depression Scale (ADS-L); stress with Perceived Stress Questionnaire (PSQ) and anxiety with General Anxiety Disorder-7 (GAD-7).
|
30870379 |
2019 |
|
Depressive Symptoms
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Anxiety and depressive symptoms were assessed with GAD-7 and PHQ-9 scales, respectively.
|
31054446 |
2019 |
|
Depressive Symptoms
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
When assessing outcomes among those with depressive symptoms at baseline (PHQ-9 > 15), we observed significant changes in PSS, GAD-7, and PHQ-9.
|
30907678 |
2019 |
|
Depressive Symptoms
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Presence and frequency of depressive symptoms and anxiety were assessed by Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder Questionnaire (GAD-7).
|
30599337 |
2019 |
|
Depressive Symptoms
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Secondary outcomes included clinician documentation of a goals-of-care conversation in the medical record and patient-reported quality of communication (Quality of Communication questionnaire [QOC]; 4-indicator latent construct) at 2 weeks, as well as patient assessments of goal-concordant care at 3 months and patient-reported symptoms of depression (8-item Patient Health Questionnaire; PHQ-8) and anxiety (7-item Generalized Anxiety Disorder survey; GAD-7) at 3 and 6 months.
|
29802770 |
2018 |
|
Depressive Symptoms
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this single-centre approach, n = 1,000 adolescents will be screened (using PHQ-9 and GAD-7), and adolescents with results indicative of anxiety or depressive symptoms (n = 162) will be advised to seek psychological health care in clusters from treating physicians in specialised outpatient departments.
|
30428891 |
2018 |
|
Depressive Symptoms
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Primary outcome measures will assess anxiety and depressive symptoms using the GAD-7 and PHQ-9, respectively.
|
29499675 |
2018 |
|
Depressive Symptoms
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Between August and September 2016, 56 Arabic speaking asylum seekers placed among three collective accommodation centers in Erlangen completed self-report questionnaires assessing posttraumatic stress disorder (Essen Trauma-Inventory, ETI), and symptoms of depression (Patient Health Questionnaire-depression module, PHQ-9) and anxiety (Generalized Anxiety Disorder, GAD-7).
|
28590438 |
2017 |
|
Depressive Symptoms
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Symptoms of depression and anxiety were measured using the Patient Health Questionnaire (PHQ-9) and the General Anxiety Disorder-7 (GAD-7).
|
29025788 |
2017 |